Phaseline

Targets › BRD4

BRD4 (Bromodomain-containing protein 4): drug programs, companies and trials

5 programs from 5 companies in 20 trials: 15 Phase 1, 3 Phase 3, 2 Phase 2; Oncology, Other, Infectious disease; next expected readout Nov 2026.

Chromatin reader protein that recognizes and binds acetylated histones and plays a key role in transmission of epigenetic memory across cell divisions and transcription regulation. Remains associated with acetylated chromatin throughout the entire cell cycle and provides epigenetic memory for postmitotic G1 gene transcription by preserving acetylated chromatin status and maintaining high-order chromatin structure. (UniProt, O60885)

Open in Phaseline: the race on BRD4, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
NovartisPelabresib
Bromodomain and extra-terminal motif (BET) inhibitor
BRD2, BRD4, BRDT, BRD3Phase 3Hematologic Malignancy; Myelofibrosis; Primary Myelofibrosis (PMF); Healthy Participants …Nov 2026
National Cancer Institute (NCI)ZEN003694 (ZEN-3694)
BET bromodomain inhibitor
BRD2, BRD3, BRD4Phase 2Advanced Malignant Solid Neoplasm; Metastatic Colorectal Adenocarcinoma; Anatomic Stage III Breast Cancer AJCC v8; Advanced NUT Carcinoma …Dec 2026
ResverlogixApabetalone (RVX000222)
Bromodomain and extra-terminal motif (BET) inhibitor
BRD2, BRD4, BRDT, BRD3Phase 2Post-Acute COVID-19 Syndrome–
Chia Tai Tianqing Pharmaceutical GroupTQB3617 Capsules
Bromodomain and Extra-Terminal (BET) inhibitor
BRD2, BRD3, BRD4, BRDTPhase 1MyelofibrosisDec 2026
Bristol-Myers SquibbEzobresib (BMS-986158)
Bromodomain and extra-terminal motif (BET) inhibitor
BRD2, BRD4, BRDT, BRD3Phase 1Multiple Myeloma; MyelofibrosisAug 2028

Conditions

Myelofibrosis (3) Advanced Malignant Solid Neoplasm (3) Primary Myelofibrosis (PMF) (2) Anatomic Stage III Breast Cancer AJCC v8 (2) Hematologic Malignancy (1) Healthy Participants (1) Advanced Malignancies (1) Advanced Malignancies and Hepatic Impairment (1) Metastatic Colorectal Adenocarcinoma (1) Advanced NUT Carcinoma (1) Recurrent Endometrial Carcinoma (1) Metastatic Colorectal Carcinoma (1)

Modalities

small molecule (5)

Companies

Novartis (1) Chia Tai Tianqing Pharmaceutical Group (1) National Cancer Institute (NCI) (1) Bristol-Myers Squibb (1) Resverlogix (1)

Related targets

BRD2 (5) BRD3 (5) BRDT (4)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.